NDAVAGINALGEL
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
NUVESSA (metronidazole) by Galderma is [see microbiology ( )]. First approved in 2014.
Drug data last refreshed 42m ago · AI intelligence enriched 42m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUVESSA is a vaginal gel formulation of metronidazole, a nitroimidazole antimicrobial indicated for bacterial vaginosis in women. It works by disrupting bacterial DNA and cell wall integrity. The product represents a specialized delivery approach to a well-established active ingredient.
$0.110BPart D
Peak5.6 years to LOEProduct is at peak lifecycle with modest Part D spending ($110K annually), suggesting stable but limited commercial footprint with smaller brand team requirements.
Mechanism of Action
[see Microbiology ( )].
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
Started Mar 2026
120 enrolled
Bacterial Vaginosis (BV)
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Started Jan 2025
30 enrolled
PHA1A
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Started May 2023
48 enrolled
Rosacea
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Started Aug 2021
13 enrolled
Crohn DiseasePediatric Crohns Disease
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Started Mar 2019
268 enrolled
Complicated Intra-abdominal Infections
Worked on NUVESSA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.